drugset
drugset / Trial / NCT04655599

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

NCT04655599 ↗

Phase 1 Terminated 1 enrolled Arena Pharmaceuticals
RandomizedCrossoverDouble-blindBasic science

Summary

A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).

Timeline

Start
2021-01-29
Primary completion
2021-04-13
Completion
2021-04-13

Outcome

Outcome not reported

Stopped (Business): “Strategic business decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject Olorinab Small molecule — Oral

Indications

irritable bowel syndrome